Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure

Erythropoiesis stimulating agent (ESA) treatment failure is associated with poor prognosis for patients with IPSS[1][1] low and intermediate-1 (‘lower risk’) myelodysplastic syndromes (MDS)[2][2] and, to date, there is no standard treatment option. In this subgroup of patients, disease modifying

[1]  B. Esterni,et al.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Garcia-Manero,et al.  Hypomethylating agents and other novel strategies in myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Musto,et al.  Azacitidine for the treatment of lower risk myelodysplastic syndromes , 2010, Cancer.

[4]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[5]  R. Stone.  How I treat patients with myelodysplastic syndromes. , 2009, Blood.

[6]  J. Hainsworth,et al.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[8]  H. Dombret,et al.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.

[9]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[10]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[11]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[12]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.